Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 11, 2011, Pages 989-994

  Tyson, Gia L ^a,b   Duan, Zhigang ^a,b   Kramer, Jennifer R ^a,b   Davila, Jessica A ^a,b   Richardson, Peter A ^a,b   El Serag, Hashem B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blood test; Epidemiology; Liver disease; Prognosis; Risk

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER MORTALITY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; UNITED STATES;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 80054985207     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.07.026     Document Type: Article

References (28)

1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
2. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
3. But D.Y., Lai C.L., Yuen M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008, 14:1652-1656.
4. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
5. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
6. Chevret S., Trinchet J.C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999, 31:133-141.
7. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998, 28:751-755.
8. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989, 64:1700-1707.
9. Peng S.Y., Chen W.J., Lai P.L., et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004, 112:44-50.
10. Chen T.H., Chen C.J., Yen M.F., et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002, 98:257-261.
11. Sakar B., Ustuner Z., Karagol H., et al. Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 2004, 27:489-493.
12. Izumi R., Shimizu K., Kiriyama M., et al. Alpha-fetoprotein production by hepatocellular carcinoma is a prognostic of poor patient survival. J Surg Oncol 1992, 49:151-155.
13. Tanizaki H., Ryu M., Kinoshita T., et al. Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn J Clin Oncol 1997, 27:67-70.
14. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31:840-845.
15. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
16. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
17. Backus L.I., Gavrilov S., Loomis T.P., et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009, 16:775-783.
18. El-Serag H.B., Kramer J.R., Chen G.J., et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011, 60:992-997.
19. Davila J.A., Weston A., Smalley W., et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007, 41:777-782.
20. Kramer J.R., Davila J.A., Miller E.D., et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008, 27:274-282.
21. md+calc. MELD score (Model for End-Stage Liver Disease) (12 and older) Accessed July 2010. http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older.
22. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
23. Lin D., Wei L., Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993, 80:557-572.
24. Levy I., Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002, 50:881-885. Liver Cancer Study Group of the University of Toronto.
25. Farinati F., Rinaldi M., Gianni S., et al. How should patients with hepatocellular carcinoma be staged?. Validation of a new prognostic system. Cancer 2000, 89:2266-2273.
26. Ueno S., Tanabe G., Sako K., et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001, 34:529-534.
27. Henderson J.M., Sherman M., Tavill A., et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) 2003, 5:243-250.
28. Hsu C.Y., Huang Y.H., Hsia C.Y., et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010, 53:108-117.